Skip to main
LVTX
LVTX logo

LVTX Stock Forecast & Price Target

LVTX Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

LAVA Therapeutics NV is strategically positioned within the clinical stage immuno-oncology sector, focusing on a proprietary Gammabody platform that aims to revolutionize cancer treatment through the development of bispecific antibodies targeting undisclosed tumor-associated antigens. The company’s diverse pipeline features promising products, including LAVA-1266, LAVA-1427, and LAVA-1433, which collectively exhibit significant potential to address unmet medical needs in cancer therapeutics. Furthermore, a recent definitive agreement with XOMA Royalty suggests a proactive approach to financial management and collaboration, enhancing LAVA's cash position while potentially solidifying its market presence in the immuno-oncology landscape.

Bears say

LAVA Therapeutics has announced the discontinuation of its Phase 1 study of LAVA-1266, which suggests significant setbacks in its drug development pipeline. The company's decision to wind down this program coincides with a pending acquisition, raising concerns about the overall viability of its research initiatives. Additionally, the reduction of the price target from $1.50 to $1.24 indicates a re-evaluation of the company's financial outlook and may reflect diminishing confidence among investors.

LVTX has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LAVA Therapeutics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LAVA Therapeutics NV (LVTX) Forecast

Analysts have given LVTX a Hold based on their latest research and market trends.

According to 4 analysts, LVTX has a Hold consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LAVA Therapeutics NV (LVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.